CN Bio Innovations Ltd.. (2/27/19). "Press Release: CN Bio to Put Ten Organs on “Body-on-a-Chip”". London.

	Organisation	CN Bio Innovations Ltd.
	Group	CN Innovations (Group)
	Organisation 2	MIT (Massachusetts Institute of Technology)
	Product	organ-on-a-chip technology
	Product 2	PhysioMimix® Organs-on-Chips system
	Index term	CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio
	Person	Hughes, David (CN Innovations 201807– CEO at CN Bio Innovations before CTO joined 2010 before GSK)

Organ-on-Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of Technology for Organ-on-Chip systems which connect human tissues from up to 10 organs.

CN Bio participated with MIT on a US$26M DARPA federal contract to develop a Human-Body-on-Chip system. In an article published in Nature Scientific Reports in March 2018, MIT researchers and CN Bio announced the successful final milestone of this program to bring 10 organs together on a chip.

CN Bio CEO Dr David Hughes said: “Scientists currently lack adequate means to determine whether a new drug to treat one organ is likely to have adverse effects on another. At present much of this information comes from poorly predictive animal studies. Many costly drug failures take place because we lack the ability to generate human relevant data in the laboratory – this is exactly the data which our PhysioMimix Multi-Organ-on-Chip studies will provide.

“These MIT patents extend our portfolio to cover multi-organ systems. We believe multi-organ safety and efficacy studies can bridge a serious gap in drug development between simple pre-clinical in vitro tests and difficult and expensive animal testing.

“By recreating human organ interactions on CN Bio’s smart-phone sized chip, scientists can measure the effects of drugs or other chemicals on different tissues of the body.”

The CN Bio team is building the multi-organ consumable plates to be compatible with its award-winning PhysioMimix benchtop Organ-on-Chip system.

PhysioMimix is a printer-sized device with open-well plates where micro-tissues that mimic the structure and function of human organs and tissues can be cultured. Linking two or more of these miniature systems using microfluidics means multiple organs interact and respond to stimuli.

Launched in May 2018, PhysioMimix is being used by pharmaceutical and consumer goods companies globally and by the US Food and Drug Administration (FDA) to conduct Organ-on-Chip assays.

Scientists use the device to culture micro-tissues that mimic the structure and function of human organs and run a wide range of assays and experiments. These provide essential data on how a new drug, food additive, cosmetic or chemical will affect the key organs in our bodies.

The multi-organ patents have been licensed from the MIT School of Biological Engineering, laboratory of Professor Linda Griffith.

CN Bio expects multi-organ consumable plates for PhysioMimix system to be available later in 2019. Early multi-organ studies will provide data on how drugs and chemicals interact within a gut-liver or lung-liver systems, two in-demand models for understanding drug metabolism and therapeutic safety respectively.

Enquiries:
sales@cn-bio.com
+44 (0)1707 358 739

About PhysioMimix Multi-Organ-on-Chip device and CN Bio Innovations

CN Bio Innovations develops devices that boost the precision and speed of biological research. By predicting the effects chemical and biological substances will have on human organs, researchers can fast-track improvements in healthcare.

The PhysioMimix lab-benchtop device can be used to perform single-organ or multi-organ studies. Its open-well plates enable the formation of three-dimensional micro-tissues that mimic the structure and function of human organs. Linking two or more of these systems using microfluidics can reveal how multiple organs interact and respond to drugs or other chemicals. Cells and media can be sampled throughout experiments for analysis including biomarker assays, imaging to visualize cell morphology, cell migration and protein marker localization.

Researchers in biopharma, academic and regulatory laboratories globally are using PhysioMimix to study primary cells, stem cells, and organ mimetics including include liver, lung, gut, heart, kidney, skin, endometrium and brain.

Spun out from the University of Oxford, CN Bio is collaborating with and developing intellectual property from several leading UK and US universities including MIT, and is co-recipient of a grant from Defense Advanced Research Projects Agency (DARPA) for a 10-organ “Human-Body-on-a-Chip”.

For more information, visit www.physiomimix.com and cn-bio.com

Record changed: 2023-06-05